Ondexxya approved in Japan for FXai reversal
29 March 2022 07:00 BST Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding Ondexxya (andexanet alfa)has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The approval by the Japanese Ministry of